Skip to main content

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, ELISA Capture (Matched Antibody Pair), ELISA Detection (Matched Antibody Pair), ELISA Standard (Matched Pair), Flow Cytometry, Neutralization

Label

DyLight 488 (Excitation = 493 nm, Emission = 518 nm)

Antibody Source

Recombinant Monoclonal Mouse IgG1 Clone # 194128

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Siglec‑5/Siglec‑14
Lys18-Thr434
Accession # O15389

Reactivity Notes

0

Specificity

Detects human Siglec‑5/Siglec‑14 in ELISAs. In sandwich immunoassays, 100% cross-reactivity with recombinant human (rh) Siglec-14 is observed and no cross-reactivity with rhSiglec-3, rhSiglec-7, or rhSiglec-9 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for Siglec-5/Siglec-14 Antibody (194128) [DyLight 488]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

ELISA Capture (Matched Antibody Pair)

Optimal dilutions of this antibody should be experimentally determined.

ELISA Detection (Matched Antibody Pair)

Optimal dilutions of this antibody should be experimentally determined.

ELISA Standard (Matched Pair)

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Neutralization

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Siglec-5/Siglec-14

Siglecs are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal, Ig-like V-type domain that mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (2 to 17), a single transmembrane region, and a cytoplasmic tail. The siglecs can be broadly classified into two subgroups: Siglecs-1, -2, and -4, and a Siglec-3/CD33-related subgroup (Siglecs-3, and -5 through -13 in primates) defined by sequence similarity and clustered gene localization. They are widely expressed on hematopoietic cells, often in a cell-type-specific manner, and Siglec-4/MAG is a myelin component in Schwann cells and oligodendrocytes. Their ligands, sialic acids, are negatively charged monosaccharides found on cell-surface glycoproteins and glycolipids. Although Siglec functions continue to be defined, most have intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM), implicating them in the suppression of immunoreceptor signaling. They may also participate in cell/cell interactions or act as receptors for the entry of viral or bacterial pathogens.

Long Name

Sialic Acid Binding Ig-like Lectin 5

Alternate Names

CD170;CD33L2;OBBP2;OB-BP2;Sialic acid-binding Ig-like lectin 5;SIGLEC5;SIGLEC-5

Gene Symbol

SIGLEC5

Additional Siglec-5/Siglec-14 Products

Product Documents for Siglec-5/Siglec-14 Antibody (194128) [DyLight 488]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Siglec-5/Siglec-14 Antibody (194128) [DyLight 488]

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...